ALXO — ALX Oncology Holdings Share News
0.000.00%
Last trade - 00:00Brief: Alx Oncology Receives Ind Clearance From U.S. FDA For Alx2004
Brief: Alx Oncology Holdings Inc Files For Mixed Shelf Of Up To $364.1 Million
ALX Oncology Holdings Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Alx Oncology Holdings Inc To Reduce Workforce By 30%
ALX Oncology Holdings Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Alx Oncology Presents Positive Updated Data From Aspen-06 Phase 2 Trial
ALX Oncology Holdings Inc expected to post a loss of 72 cents a share - Earnings Preview
Brief: ALX Oncology Q3 Basic EPS USD -0.58
Brief: ALX Oncology Announces First Patients Dosed With Evorpacept And Sarclisa As Part Of Randomized Phase 1/2 UMBRELLA Study With Sanofi
Brief: Millennium Management Reports 5.6% Passive Stake In ALX Oncology Holdings
Brief: ALX Oncology Q2 Basic EPS USD -0.76
ALX Oncology Holdings Inc expected to post a loss of 77 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Spirit Airlines, Labcorp, Air Products and Chemicals
ALX Oncology down as brokerages slash PT over gastric cancer therapy trial data
U.S. RESEARCH ROUNDUP-CH Robinson Worldwide, Lam Research, Meta
Brief: Alx Oncology Presents First Evorpacept Combination Data With An Antibody-Drug Conjugate From Phase 1 Aspen-07 Clinical Trial In Patients With Advanced Bladder Cancer
ALX Oncology Holdings Inc reports results for the quarter ended in March - Earnings Summary
Brief: ALX Oncology Q1 Basic EPS USD -0.71
Brief: Alx Oncology Announces Initiation Of Phase 2 Investigator Sponsored Trial Of Neoadjuvant Radiation And Evorpacept